ASAP2

Across TCGA pan-cancer cohorts, ASAP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ASAP2 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher ASAP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ASAP2 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

GBM, CCRCC, and LUAD are the cancer types where ASAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.486	0.251	<.001	31	view →
CCRCC	DFS	Quartile	All	0.921	0.610	.009	24	view →
LUAD	OS	Tertile	III,IV	0.311	1.000	.016	9	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
HNSC	DFS	Tertile	III,IV	1.000	0.919	.042	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ASAP2–GBM (OS)

Open the GBM breakdown →